Advertisement

Implications of the Food, Drug, and Cosmetic Act on the Quality Assurance of Radiopharmaceuticals used in the United States

  • R. Kishore
  • Eric B. Sheinin

Abstract

The drug (defined in part as any article intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease) sections of the Federal Food, Drug, and Cosmetic Act (Title 21 U.S.C.) are intended to assure the consumer that drugs are safe and effective for their intended use. The Act requires that “new drugs” be approved by the FDA before they go on the market. The Act also prohibits importation or distribution of drugs that are adulterated (defective, unsafe or filthy) or misbranded (false, misleading statements or labeling). The regulations for the new drug review process are contained in the Code of Federal Regulations (CFR) Title 21, sections 312 for Investigational New Drugs (INDs) and 314 for New Drug Applications (NDAs). Section 361 deals with radioactive drugs for certain research (RDR) uses. The regulations require that sufficient information be provided on the acceptable limits and the analytical methods used for the assurance of the identity, strength, quality, purity and the stability of the new drug as well as the raw materials used in the preparation of the new drug. The impact of the Act on the control of radiopharmaceutical products will be discussed.

Keywords

Drug Product High Pressure Liquid Chromatography Drug Substance Unite States Pharmacopeia Radionuclidic Purity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Federal Food, Drug, and Cosmetic Act, as Amended, and Related Laws, 1986.Google Scholar
  2. 2.
    Code of Federal Regulations, Chapter 21, 1990.Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • R. Kishore
    • 1
  • Eric B. Sheinin
    • 1
  1. 1.Center for Drug Evaluation and ResearchU.S. Food and Drug AdministrationRockvilleUSA

Personalised recommendations